Political Wrinkles  

Go Back   Political Wrinkles > General Discussion > Health, Wellness, Sex and Body
Register FAQDonate PW Store PW Trivia Members List Calendar Search Today's Posts Mark Forums Read

Health, Wellness, Sex and Body Discuss Leukemia & Lymphoma research & treatment at the General Discussion; First Gene Therapy for Deadly Childhood Cancer... What Families Need to Know About First Gene Therapy for Deadly Childhood Cancer ...

Reply
 
Share LinkBack Thread Tools Display Modes
  #1 (permalink)  
Old 07-16-2017, 05:41 AM
Master
 
Join Date: Dec 2011
Location: Okolona
Gender: Male
Posts: 1,307
Thanks: 973
Thanked 357 Times in 299 Posts
Lightbulb Leukemia & Lymphoma research & treatment

First Gene Therapy for Deadly Childhood Cancer...

What Families Need to Know About First Gene Therapy for Deadly Childhood Cancer
July 14, 2017 - An advisory panel to the Food and Drug Administration earlier this week unanimously recommended approving a breakthrough genetic therapy to treat a rare but deadly type of childhood cancer. Here's why the news has cancer researchers excited—and what it means for families with children diagnosed with the cancer.
Quote:
What Is the New Gene Therapy?

The new therapy, developed by the Swiss drug company Novartis, is known as as CTL019 (tisagenlecleucel). It’s sometimes referred to as a “living drug,” because it relies on using a patient's own immune system to fight cancer. Doctors take a type of white blood cell called T-cells from a patient’s bloodstream, genetically modify them to attack cancer cells (as shown in the image above), then infuse them back into the patient. “This opens up a whole new world for cancer research and treatment,” says Gwen Nichols, M.D., chief medical officer of the Leukemia & Lymphoma Society, a nonprofit organization that helped fund research on the therapy.

Who Might Benefit From It?

The drug is meant to help children with B-cell acute lympoblastic leukemia (ALL) who don't respond to chemotherapy, radiation, and other existing treatments. There are about 2,500 cases of ALL in the U.S. each year, and about 620 children who don't recover with that standard care. The FDA advisory panel recommended approval based mainly on a Novartis trial, which found that among 63 such patients treated with CTL019, 52 went into remission. The therapy is intended as a last resort for children who “would otherwise die in a matter of weeks,” Nichols says. That's because the therapy, while potentially lifesaving, also carries serious risks, including a life-threatening reaction called cytokine release syndrome.


When Will the Therapy Be Available?

The FDA will make a final decision on the drug by October 2017, according to Novartis spokesperson Julie Masow. The approval of the therapy is contingent upon Novartis' response to a number of issues, including chemistry, manufacturing, and safety questions. CTLO19 was designated as a "breakthrough therapy" by the FDA back in 2014, which the agency grants to drugs that treat serious or life-threatening conditions and that demonstrate the potential to be significantly more effective than existing therapies.


But because of the complexity and novelty of the CTL019, says Masow, it will initially be offered at just 30 to 35 treatment centers in the U.S. "This strategy will help ensure that each site is fully prepared with the necessary infrastructure in place to support the special ordering, cell collection, chain of identity, use, and site-level care associated with CTL019," Masow says.

How Much Will It Cost?
__________________
The water's always turbulent where two great rivers meet.
Reply With Quote
Reply

Tags
and, leukemia, lymphoma, research, treatment

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are On

Forum Jump


All times are GMT -5. The time now is 07:51 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2017, vBulletin Solutions, Inc.

Content Relevant URLs by vBSEO 3.2.0